Dose-finding Study in Platinum-Resistant Ovarian Cancer
Phase 1
Completed
- Conditions
- Recurrent Platinum-resistant Ovarian Cancer
- Interventions
- Drug: GSK2110183 in combination with carboplatin and paclitaxel
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 59
- Registration Number
- NCT01653912
- Locations
- ๐ฆ๐บ
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
๐ฌ๐งImperial College Healthcare NHS Trust, London, United Kingdom
๐ฆ๐บSir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
Phase 2
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 131
- Registration Number
- NCT01507194
- Locations
- ๐บ๐ธ
Visions Clinical Research, Boynton Beach, Florida, United States
๐บ๐ธCAP Anesthesia (St. Elizabeth's Medical Center), Boston, Massachusetts, United States
๐บ๐ธUniversity of Pittsburg, Pittsburgh, Pennsylvania, United States
Single Dose Study of GSK1440115 in Patients With Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: 1440115Drug: Placebo
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 12
- Registration Number
- NCT01424280
- Locations
- ๐ฆ๐บ
Investigational Site, New South Wales, Australia
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
Phase 1
Completed
- Conditions
- Post-Operative Nausea and Vomiting (PONV)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Accenture
- Target Recruit Count
- 55
- Registration Number
- NCT01290133
- Locations
- ๐ฆ๐บ
Investigational Site, Melbourne, Victoria, Australia
Repeat Dose Safety Study for Compound to Treat Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: 1440115Drug: Placebo
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Accenture
- Registration Number
- NCT01202214
- Locations
- ๐ฆ๐บ
Investigational Site, Melbourne, Australia
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
Phase 1
Completed
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: GSK21110183
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Accenture
- Target Recruit Count
- 73
- Registration Number
- NCT00881946
- Locations
- ๐จ๐ฆ
Princess Margaret Hospital, Toronto, Ontario, Canada
๐ฆ๐บPrince of Wales Hospital, Sydney, New South Wales, Australia
๐ฆ๐บThe Alfred Hospital, Melbourne, Victoria, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath